Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation by Schlange, Thomas et al.
Open Access
Available online http://breast-cancer-research.com/content/9/5/R63
Page 1 of 15
(page number not for citation purposes)
Vol 9 No 5 Research article
Autocrine WNT signaling contributes to breast cancer cell 
proliferation via the canonical WNT pathway and EGFR 
transactivation
Thomas Schlange1, Yutaka Matsuda1, Susanne Lienhard1, Alexandre Huber1,2 and 
Nancy E Hynes1
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
2Université de Genève, Département de biologie moléculaire, Sciences II, 30 quai Ernest-Ansermet, CH-1211 Genève 4, Switzerland
Corresponding author: Nancy E Hynes, nancy.hynes@fmi.ch
Received: 20 Jun 2007 Revisions requested: 3 Aug 2007 Revisions received: 19 Sep 2007 Accepted: 26 Sep 2007 Published: 26 Sep 2007
Breast Cancer Research 2007, 9:R63 (doi:10.1186/bcr1769)
This article is online at: http://breast-cancer-research.com/content/9/5/R63
© 2007 Schlange et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background De-regulation of the wingless and integration site
growth factor (WNT) signaling pathway via mutations in APC
and Axin, proteins that target β-catenin for destruction, have
been linked to various types of human cancer. These genetic
alterations rarely, if ever, are observed in breast tumors.
However, various lines of evidence suggest that WNT signaling
may also be de-regulated in breast cancer. Most breast tumors
show hypermethylation of the promoter region of secreted
Frizzled-related protein 1 (sFRP1), a negative WNT pathway
regulator, leading to downregulation of its expression. As a
consequence, WNT signaling is enhanced and may contribute
to proliferation of human breast tumor cells. We previously
demonstrated that, in addition to the canonical WNT/β-catenin
pathway, WNT signaling activates the extracellular signal-
regulated kinase 1/2 (ERK1/2) pathway in mouse mammary
epithelial cells via epidermal growth factor receptor (EGFR)
transactivation.
Methods Using the WNT modulator sFRP1 and short
interfering RNA-mediated Dishevelled (DVL) knockdown, we
interfered with autocrine WNT signaling at the ligand-receptor
level. The impact on proliferation was measured by cell counting,
YOPRO, and the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) assay; β-catenin, EGFR, ERK1/2
activation, and PARP (poly [ADP-ribose]polymerase) cleavages
were assessed by Western blotting after treatment of human
breast cancer cell lines with conditioned media, purified
proteins, small-molecule inhibitors, or blocking antibodies.
Results Phospho-DVL and stabilized β-catenin are present in
many breast tumor cell lines, indicating autocrine WNT signaling
activity. Interfering with this loop decreases active β-catenin
levels, lowers ERK1/2 activity, blocks proliferation, and induces
apoptosis in MDA-MB-231, BT474, SkBr3, JIMT-1, and MCF-7
cells. The effects of WNT signaling are mediated partly by EGFR
transactivation in human breast cancer cells in a
metalloprotease- and Src-dependent manner. Furthermore,
Wnt1 rescues estrogen receptor-positive (ER+) breast cancer
cells from the anti-proliferative effects of 4-hydroxytamoxifen (4-
HT) and this activity can be blocked by an EGFR tyrosine kinase
inhibitor.
Conclusion Our data show that interference with autocrine
WNT signaling in human breast cancer reduces proliferation
and survival of human breast cancer cells and rescues ER+
tumor cells from 4-HT by activation of the canonical WNT
pathway and EGFR transactivation. These findings suggest that
interference with WNT signaling at the ligand-receptor level in
combination with other targeted therapies may improve the
efficiency of breast cancer treatments.
4-HT = 4-hydroxytamoxifen; ADAM = A Disintegrin And Metalloprotease; CM = conditioned medium; CRC = colorectal cancer; DMEM = Dulbecco's 
modified Eagle's medium; DVL = Dishevelled; EGF = epidermal growth factor; EGFR = epidermal growth factor receptor; ER = estrogen receptor; 
ERK1/2 = extracellular signal-regulated kinase 1/2; FCS = fetal calf serum; FZD = Frizzled; Gα = heterotrimeric G protein subunit α; GFP = green 
fluorescent protein; GPCR = G protein-coupled receptor; HRP = horseradish peroxidase; IP = immunoprecipitation; MEF = mouse embryonic fibro-
blast; MMP = matrix metalloprotease; PARP = poly(ADP-ribose)polymerase; PgR = progesterone receptor; PTX = pertussis toxin; sFRP1 = secreted 
Frizzled-related protein 1; shRNA = short hairpin RNA; siRNA = short interfering RNA; TCF = T-cell factor; TKI = tyrosine kinase inhibitor; Tyr = tyro-
sine; WNT = wingless and integration site growth factor.Breast Cancer Research    Vol 9 No 5    Schlange et al.
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Introduction
Growth factors of the wingless and integration site growth fac-
tor (WNT) family are secreted, glycosylated, and palmitoylated
peptides that interact with seven-transmembrane receptors of
the Frizzled (FZD) family. Diverse signaling pathways are acti-
vated upon WNT/FZD binding. The ligand/receptor interac-
tion has been shown to induce the phosphorylation of
scaffolding proteins of the Dishevelled (DVL) family by casein
kinase Iε and -2 and PKCα [1-3]. This event was reported to
be a component of all WNT-induced signaling pathways [4,5].
The so-called canonical WNT signaling pathway leads to sta-
bilization of β-catenin through inactivation of a protein complex
consisting of, amongst others, the tumor suppressors APC
and Axin. This destruction complex normally triggers rapid β-
catenin phosphorylation, inducing its ubiquitination and degra-
dation. In the presence of canonical WNT ligands, β-catenin is
stabilized, binds transcription factors of the LEF-1/T-cell factor
(TCF) family, and stimulates target gene transcription [6].
Aberrant activation of the WNT signaling pathway plays an
important role in the development of many human cancer
types. In colorectal cancer (CRC), mutations in APC, axin, or
β-catenin itself promote β-catenin stabilization and transcrip-
tion of target genes encoding cancer-associated proteins [7].
In contrast to CRC, WNT pathway mutations rarely, if ever, are
detected in breast tumors [8]. However, various lines of evi-
dence suggest that, in breast cancer, the WNT pathway may
be de-regulated by loss of expression of negative pathway reg-
ulators. For example, expression of the extracellular inhibitor of
WNT signaling, secreted Frizzled-related protein 1 (sFRP1),
which competes with FZD receptors for ligand binding, is
downregulated in many breast tumors and is associated with
poor prognosis [9-11]. Furthermore, many studies have
reported that WNT ligands and FZD receptors are expressed
in human breast cancer cell lines and primary tumors [7,12-
14]. Finally, β-catenin is frequently found stabilized and
nuclear in human breast tumors and this finding has been
associated with poor prognosis [15]. Taken together, these
observations suggest that WNT signaling may frequently be
de-regulated in breast cancer.
We have previously described a novel crosstalk between
WNT signaling and epidermal growth factor receptor (EGFR)
[16]. The mechanism, which we have shown to involve activa-
tion of zinc-dependent membrane-associated metallopro-
teases [16] that control the cleavage and availability of ERBB
ligands [17], appears to be analogous to that described for
transactivation of EGFR triggered by stimulation of G protein-
coupled receptors (GPCRs) [18]. GPCR-mediated EGFR
transactivation involves various heterotrimeric G protein α
subunits, activation of PKC and/or Src kinase, as well as
ADAMs (A Disintegrin And Metalloprotease) (reviewed
recently in)[19]) or matrix metalloprotases (MMPs) [20].
In this study, we provide evidence for constitutive autocrine
WNT signaling in human breast cancer cells. We show that
sFRP1 blocks proliferation of many breast tumor cell lines
through interference with pathway activation that is presuma-
bly driven by endogenous WNT ligands. Thus, our study
clearly demonstrates that sFRP1 fulfills its proposed tumor
suppressor function [21]. Downstream of the WNT ligand/
FZD receptor interaction, knockdown of DVL expression using
short interfering RNA (siRNA) also results in a proliferative
reduction and the induction of apoptosis in many human
breast cancer cell lines. Our results, showing that Wnt1 trans-
activates EGFR in tumor cell lines, imply that, in breast cancer,
constitutive WNT signaling might impact not only on the
canonical pathway, but also on EGFR activity by stimulating
ligand availability. Considering that constitutive ERBB recep-
tor activation is an important mechanism promoting cancer cell
proliferation, migration [22,23], and sensitivity to anti-cancer
therapies [24], approaches to target WNT pathway activity
might be appropriate as an anti-cancer strategy.
Materials and methods
Reagents
The following antibodies were used in this study: extracellular
signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, total β-cat-
enin, poly(ADP-ribose)polymerase (PARP), EGFR, p-EGFR
(tyrosine [Tyr] 845), and p-Tyr-100 (Cell Signaling Technol-
ogy, Inc., Danvers, MA, USA); c-MYC (9E10), DVL2 and
DVL3, EGFR 528, 1005, and R1 (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA); Wnt1 and DVL1 (R&D Systems
Europe, Abingdon, UK); active β-catenin (anti-ABC; Upstate,
now part of Millipore Corporation, Billerica, MA, USA); and α-
Tubulin (Lab Vision Corporation, Fremont, CA, USA). As sec-
ondary antibodies, α-rabbit and α-mouse (GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK, and LI-COR Biosciences,
Lincoln, NE, USA) or α-goat (DAKO A/S, Glostrup, Denmark)
coupled to horseradish peroxidase (HRP) were used. Mouse
Wnt1 in the retroviral vector pLNCX was obtained from
Andrew McMahon (Harvard University, Cambridge, MA, USA);
the cDNA encoding human sFRP1 in pcDNA was provided by
Jeffrey Rubin (National Cancer Institute, Bethesda, MD, USA).
The retroviral vector for the expression of short hairpin RNA
(shRNA) constructs pSUPERretro Neo green fluorescent pro-
tein (GFP) was provided by Francois Lehembre (DKBW,
Basel, Switzerland). PKI166 and AEE788 were provided by
Peter Traxler (Novartis Pharma AG, Basel, Switzerland);
CGP77675 was provided by Jonathan Green and Mira Susa
Spring (Novartis Pharma AG), and CGS27023A was pro-
vided by Ulf Neumann (Novartis Pharma AG). 4-Hydroxyta-
moxifen (4-HT) was purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Cell culture, transfections, and retroviral infections
The human breast cancer cell lines T47D, MCF-7, ZR-75.1,
SkBr3, BT474, and MDA-MB-231 (American Type Culture
Collection, Manassas, VA, USA) and JIMT-1 (DSZM, Braun-Available online http://breast-cancer-research.com/content/9/5/R63
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schweig, Germany) were cultivated in Dulbecco's modified
Eagle's medium (DMEM), 10% heat-inactivated fetal calf
serum (FCS) (Amimed, Allschwil, Switzerland) supplemented
with penicillin and streptomycin. HC11 and HC11/Wnt1 cells
were maintained in RPMI 1640, 10% FCS, penicillin/strepto-
mycin, epidermal growth factor (EGF) (Collaborative Research
Co., Bedford, MA, USA) and insulin (Sigma-Aldrich). HC11/
Wnt1 cells were kept under selection in 1 mg/mL G-418 (Life
Technologies, Inc., now part of Invitrogen Corporation,
Carlsbad, CA, USA). HEK 293 cells were transfected with a
vector encoding myc/HIS-tagged human sFRP1 using Lipo-
fectamine according to the manufacturer's guidelines. Cells
were kept for 3 weeks in medium containing 1.5 mg/mL G-
418, and clones were selected. T47D and SkBr3 cells were
stably transfected with Wnt1 or empty pLNCX as control by
Lipofectamine Reagent (Invitrogen Corporation) according to
the manufacturer's instructions. Clones of Wnt1-expressing
cells were selected with 0.5 mg/mL G-418. The expression of
Wnt1 ligand was verified by Western blotting, and biological
activity was assayed in a co-culture assay with HEK 293/8×
SUPERTopFlash cells, using 300,000 cells each in a six-well
overnight culture before the assay was performed. Knock-
down of β-catenin was achieved by retroviral infection [25]
with pSUPERretro Neo GFP containing a short-hairpin target-
ing β-catenin [26]. A construct targeting bacterial LacZ (sense
strand gCggCTgCCggAATTTACCdTdT) was used as con-
trol. Clones and a pool of cells with low levels of β-catenin
were analyzed for their response to Wnt1 condition medium
(CM). Src-/- mouse embryonic fibroblasts (MEFs), provided by
Kurt Ballmer (Paul Scherrer Institut, Villigen, Switzerland),
were transfected with empty vector or a c-Src-expressing vec-
tor, and clones were selected. Src re-expressing MEFs were
generated by Monilola Olayioye (University of Stuttgart,
Germany).
siRNA transfections
Five hundred thousand cells per well were seeded in a six-well
plate the day before transfection and were transfected with
either 50 nM control RNA duplex targeting bacterial LacZ
(sense strand gCggCUgCCggAAUUUACCdTdT) or a mixture
of two siRNA duplexes (25 nM each; Qiagen GmbH, Hilden,
Germany) targeting bases 1420 to 1440 (gCUCAACAAgAU-
CACCUUCUdTdT) in human DVL1 (NM_004421) and bases
1754 to 1774 and 1579 to 1599 (gUCAACAAgAUCACCU-
UCUdTdT) in human DVL2 (NM_004422) and DVL3
(NM_004423), respectively, using HiPerfect (Qiagen GmbH)
according to the manufacturer's instructions. The DVL target
sequences were chosen based on the high conservation in all
three human DVL homologues. The cells were cultured for 72
hours, and knockdown efficiency was monitored by Western
blotting.
Conditioned media
Confluent HC11/Wnt1 or parental HC11 cells were cultured
for 3 days in RPMI 1640, 10% FCS, penicillin/streptomycin
without EGF, insulin, and G-418. The supernatant was filtered
through a 0.25-μm syringe filter (Sarstedt AG & Co., Nümbre-
cht, Germany). Biological activity of Wnt1 CM and control CM
was assayed by their ability to induce β-catenin/TCF-depend-
ent luciferase reporter activity in HEK 293/8× SUPERTop-
Flash cells (provided by Feng Cong, Novartis Institutes for
BioMedical Research, Cambridge, MA, USA).
sFRP1 CM was obtained from HEK 293 cells transfected with
myc/HIS-tagged human sFRP1 cDNA. CM was collected and
sFRP1 activity was assayed by testing its ability to block the
activation of β-catenin/TCF-driven transcription in a co-culture
of T47D/Wnt1 cells and HEK 293/8× SUPERTopFlash cells
and the reduction of DVL3 phosphorylation in T47D/Wnt1
cells. For treatment of breast cancer cell lines, confluent
sFRP1-expressing HEK 293 cells were treated overnight with
10 mM sodium butyrate in 0.1% FCS to increase sFRP1
expression. The CM was concentrated, and sodium butyrate
was removed by filtration with a Centricon Plus-70 filtration
unit (Millipore Corporation). The resulting concentrate was
diluted to the starting volume or used as a 2× concentrate and
adjusted to 10% FCS accordingly. Cell proliferation was
measured either by counting cell numbers manually or with a
Vi-Cell XR cell viability analyzer (Beckman Coulter, Nyon, Swit-
zerland), Cell Proliferation Kit I (MTT; Roche Diagnostics
GmbH, Mannheim, Germany), or YOPRO cell viability assay
(Invitrogen Corporation) according to manufacturer
instructions.
Hybridoma cells secreting the EGFR monoclonal antibody
C225 were cultured in DMEM, 10% FCS. Collected medium
was cleared by centrifugation, filtered, and used undiluted on
target cells for 2 hours prior to collection of cell lysates.
Purification of sFRP1
sFRP1 was purified by fast performance liquid chromatogra-
phy from sFRP1 CM. After 1:10 dilution in 50 mM sodium
phosphate loading buffer pH 7.0, the solution was loaded on
a 1 mL HiTrap-HIS column (GE Healthcare) that was previ-
ously loaded with 1 mL 0.5 M NiSO4 and washed with 10 col-
umn volumes of loading buffer. Elution was performed using
50 mM sodium phosphate, 100 mM NaCl pH 7.0 elution
buffer with a 3-minute step-gradient of 10 to 500 mM imida-
zole. Fractions were collected, and 1-μL aliquots were ana-
lyzed by Western blotting using a c-MYC antibody for
detection of the MYC-tag. Biological activity was assayed as
previously described for sFRP1 CM, and the identity of the
purified protein was determined by mass spectrometry.
Protein extraction, immunoprecipitation, and Western 
blotting
Cells were lysed in lysis buffer (1% Nonident P-40, 50 mM Tris
pH 7.5, 120 mM NaCl, 5 mM EDTA [ethylenediaminetetraace-
tic acid], 1 mM EGTA [ethylene glycol tetraacetic acid], 2 mM
sodium vanadate, 20 mM β-glycerophosphate, 10 μg/mLBreast Cancer Research    Vol 9 No 5    Schlange et al.
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aprotinin, 10 μg/mL leupeptin, 0.5 mM PMSF [phenylmethyl-
sulphonyl fluoride], 50 mM NaF, and 1 mM dithiothreitol) for 5
minutes on ice, and lysates were collected. For a Western
analysis, loading buffer was added to 30 to 50 μg of protein
and the samples were denatured for 10 minutes at 95°C prior
to separation on 10% polyacrylamide gels and blotting by
semi-dry transfer for 90 minutes on polyvinylidene fluoride
membrane (Millipore Corporation). Blots were pre-blocked
using 10% horse serum in TBS-T buffer for 1 hour (0.2 M
NaCl, 25 mM Tris pH 7.5, 0.5 mL/L Tween-20) and incubated
with primary antibodies at room temperature for 1 hour or at
4°C overnight, followed by 30 minutes of incubation with sec-
ondary antibodies: α-rabbit-HRP, α-mouse-HRP, or α-goat-
HRP (1:5,000). Detection of luminescence was carried out
using ECL (enhanced chemiluminescence) (GE Healthcare)
or SuperSignal West Dura (Pierce, Rockford, IL, USA) accord-
ing to manufacturer instructions. Immunoprecipitations (IPs)
and Western analyses were performed using standard proce-
dures [24,27]. EGFR IP was performed with α-EGFR 528 and
R1. Quantifications of Western blots were carried out using
the ImageQuant TL version 2005 software package from
Amersham Biosciences (now part of GE Healthcare).
Results
WNT pathway activity in human breast tumor cell lines
WNTs activate multiple intracellular signaling cascades,
including the canonical pathway that promotes β-catenin sta-
bilization and TCF-mediated transcription [6] and other non-
canonical pathways, one being Wnt-mediated EGFR transac-
tivation [16]. To explore the possibility that Wnt signaling is de-
regulated in breast cancer by autocrine pathway activation, we
examined breast cancer cell lines for signs of canonical path-
way activity and for crosstalk between WNT, EGFR, and
ERK1/2 signalling. The panel includes the luminal, estrogen
receptor-positive (ER+) T47D, MCF-7, and ZR75.1 cells, the
ERBB2-overexpressing SkBr3, JIMT-1, and BT474 cells, and
the basal B, ER-negative MDA-MB-231 cells [28].
As a consequence of WNT binding to FZD, cytoplasmic scaf-
folding proteins of the Dishevelled family (DVL1, DVL2, and
DVL3) become phosphorylated on serine and threonine resi-
dues. DVL phosphorylation is the most proximal signaling
event downstream of the WNT-mediated activation of FZD
and can be monitored by a decrease in the electrophoretic
mobility of p-DVL [4]. To date, DVL phosphorylation has been
shown to be mediated only by WNT signaling and DVL is
upstream of all known WNT-induced signaling pathways.
DVL1 and DVL3 were consistently expressed at relatively uni-
form levels in all the breast cancer cell lines, whereas DVL2
was expressed in a more differential manner (Figure 1a).
Bands corresponding to p-DVL1 and/or p-DVL3 were
detected in all of the cell lines. p-DVL2 was also high in MDA-
MB-231 cells (Figure 1a). These results suggest that WNT
signaling might be activated in an autocrine fashion in each of
the examined breast cancer cell lines.
As a read-out for activation of the canonical WNT pathway,
active, unphosphorylated β-catenin (act. β-catenin) was ana-
lyzed in these breast cancer cell lines and in a control T47D
cell line engineered to ectopically express Wnt1 (Figure 1b).
Control and T47D/Wnt1 cells have the same level of total β-
catenin. Importantly, the Wnt1-expressing T47D cells have an
approximately three-fold increase in active β-catenin levels
compared with control cells (Figure 1b), attesting to the ability
of the antiserum to measure canonical pathway activity. In the
majority of the breast tumor cell lines, active β-catenin was
Figure 1
Autocrine WNT signaling in breast cancer cell lines Autocrine WNT signaling in breast cancer cell lines. (a) Lysates from the indicated human breast cancer cell lines were analyzed by SDS-PAGE fol-
lowed by immunoblotting for Dishevelled 1 (DVL1), DVL2, and DVL3 (the upper band indicates the phosphorylated form of each), active β-catenin, 
total β-catenin, and α-Tubulin as a loading control. (b) Lysates from T47D/Wnt1 cells and vector control were analyzed by SDS-PAGE/immunoblot-
ting for active β-catenin, total β-catenin, and α-Tubulin. WB, Western blotting; WNT, wingless and integration site growth factor.Available online http://breast-cancer-research.com/content/9/5/R63
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present at various levels (Figure 1a). Only in SkBr3 cells,
which have very low total β-catenin levels, no active β-catenin
protein was detected. These results imply that the canonical
WNT signaling pathway is constitutively active in most breast
tumor cell lines.
In vitro effects of sFRP1 on proliferation of human 
breast cancer cell lines, canonical β-catenin signaling, 
and ERK activity
Since sFRP1 expression is lost in primary breast tumors and
tumor cell lines by promoter hypermethylation [10,29], this
might be one mechanism contributing to WNT pathway
activity. We therefore assessed the effect of blocking WNT
pathway activity on in vitro proliferation of breast tumor cell
lines. Treatment of T47D cells with either purified sFRP1 or
sFRP1 CM blocked their proliferation by 30% (Figure 2a,b).
Proliferation of JIMT-1, SkBr3, and MDA-MB-231 cells was
also significantly inhibited (20% to 30%) by sFRP1 CM,
whereas BT474 and MCF-7 cells were not significantly
affected by the treatment (Figure 2a).
To analyze the signaling pathways involved in the anti-prolifer-
ative activity of sFRP1, we examined its effects on canonical
WNT signaling, which, as shown above (Figure 1a), is consti-
tutively active in most of the examined breast tumor cell lines.
Treatment of T47D, BT474, and JIMT-1 cells with sFRP1 CM
caused a 10% to 20% reduction in active β-catenin levels,
whereas there was no observable decrease in MCF-7 cells
(Figure 2c, quantified below). These results suggest that, in
these three cell lines, β-catenin stabilization is at least partly
due to autocrine activation of the pathway by WNT ligands
that can be blocked from binding their cognate FZD receptor
by sFRP1.
As we have previously shown that Wnt growth factors activate
the ERK1/2 pathway in mouse mammary epithelial cells [16],
we next examined the effect of sFRP1 on ERK1/2 activity.
sFRP1 treatment lowered the basal level of p-ERK1/2 in all cell
lines analyzed with the exception of MCF-7 (Figure 2c), which
also showed no decrease in active β-catenin in response to
sFRP1. These results are in good agreement with those show-
ing that sFRP1 treatment reduced proliferation of T47D, JIMT-
1, and SkBr3 cells, but not of MCF-7 cells. In summary, these
results show that, in some breast cancer cell lines, both canon-
ical and non-canonical Wnt signaling can be blocked by
sFRP1 treatment. Furthermore, they suggest that sFRP1 has
the potential to act as an anti-proliferative agent.
siRNA-mediated knockdown of DVL reduces c-MYC 
expression and induces apoptosis
Human breast cancer cells express multiple WNT ligands and
FZD receptors [7,12-14], and it is likely that different sFRP
family members interfere with only a subset of ligands [30].
Therefore, we hypothesized that knockdown of DVL homo-
logues would lead to a stronger blockade of autocrine WNT
signaling. Introduction of two siRNAs that target the three
human DVL homologues (pan-DVL siRNA) achieved a strong
knockdown of DVL2 and DVL3 in the cells; DVL1 was
decreased approximately 50% with this siRNA (Figure 4d).
siRNA-mediated DVL knockdown blocked proliferation of
human breast cancer cells by 20% to 60% 7 days after trans-
fection as determined by cell counting after viability staining
(Figure 3a), with the most prominent effect in JIMT-1, SkBr3,
and MDA-MB-231 cells, whereas BT474 and MCF-7 cells are
less affected. As expected, DVL knockdown affects canonical
WNT signaling activity since the level of active β-catenin
decreases concomitantly with a reduction in c-MYC, a canon-
ical WNT target (Figure 3a). SkBr3 cells show no reduction in
c-MYC levels upon DVL knockdown, very likely because either
c-MYC is amplified or canonical signaling is impaired since
there is no active β-catenin in these cells. Finally, we observe
an increase in PARP cleavage after DVL knockdown in all cell
lines analyzed (Figure 3a), indicating that apoptosis is induced
in all but BT474 cells. These data show that autocrine WNT
signaling is required for proliferation and survival of human
breast cancer cells.
Downregulation of DVL in breast cancer cells lowers 
EGFR and ERK activity
Multiple mechanisms contribute to the autocrine ligand-
induced EGFR activity [31] that is detected in many human
tumors [32,33]. Given our previous results on WNT-induced
EGFR transactivation [16], we considered it possible that
WNT signaling might also play a role in some breast tumors.
Thus, we asked whether WNT signaling also contributes to
EGFR activity, concentrating on three cell lines, BT474, JIMT-
1, and SkBr3, that in addition to ERBB2 overexpression have
high levels of active EGFR and p-ERK1/2 (Figure 4a)
[24,34,35]. pan-DVL knockdown lowered EGFR activity, as
shown by a decrease in pY845 levels, and strongly reduced
ERK1/2 activity in each of these cancer cell lines (Figure 3b).
In summary, the results suggest that, in the examined breast
cancer cell lines, WNT activity contributes to autocrine EGFR
activation and ERK1/2 activity.
Wnt1 induces ERK1/2 activity independently of 
canonical WNT signaling
In light of these results, we asked whether WNT ligands
induce EGFR/ERK1/2 activation in human breast cancer cells
in a fashion similar to that in non-transformed mouse mammary
epithelial cells [16]. Wnt1 is not commercially available in a
bioactive form and our own efforts to purify the protein using
published protocols have failed. Our approaches to prove the
specificity of Wnt1 action on ERK1/2 activity relied on the use
of CM in combination with the natural WNT inhibitor sFRP1
and on ectopic expression of Wnt1 in breast cancer cell lines.
Furthermore, we knocked down expression of DVL, the central
WNT signaling mediators downstream of WNT-ligand-trig-
gered FZD activation.Breast Cancer Research    Vol 9 No 5    Schlange et al.
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Cells were treated for 20 minutes with Wnt1 CM or control
CM, and p-ERK1/2 levels were examined (Figure 4a). The ER+
tumor cells T47D, MCF-7, and ZR75.1 have low basal p-
ERK1/2 levels that strongly increased in response to Wnt1
treatment. The ERBB2-overexpressing tumor cells BT474 and
SkBr3 have high basal p-ERK1/2, and both showed a further
increase in ERK1/2 activity in response to Wnt1. p-ERK1/2
levels were not stimulated by Wnt1 treatment of MDA-MB-
231 tumor cells, which have a K-RAS mutation and high basal
ERK1/2 activity (Figure 4a) [36]. Wnt1 CM effects on ERK1/
2 activity were blocked in T47D cells simultaneously treated
with sFRP1 (Figure 4b). Similarly, when T47D/Wnt1 or
Figure 2
Treatment of human breast cancer cells with secreted Frizzled-related protein 1 (sFRP1) reduces proliferation and impairs canonical wingless and  integration site growth factor signaling and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation Treatment of human breast cancer cells with secreted Frizzled-related protein 1 (sFRP1) reduces proliferation and impairs canonical wingless and 
integration site growth factor signaling and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. (a) One thousand to 5,000 cells of 
the indicated cell lines were seeded in a 96-well plate, and proliferation was measured in a YOPRO assay after 3 days of treatment with sFRP1 con-
ditioned medium (CM) or control CM. (b) T47D cells were treated for 3 days with 30 μg/mL purified sFRP1 or phosphate-buffered saline, and cell 
numbers were measured in an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay. The results represent the mean of three 
experiments (± standard error). *p < 0.05, **p < 0.005, unpaired Student t test, comparison to corresponding control-treated cell line. (c) The indi-
cated human breast cancer cell lines were treated for 2 hours with concentrated sFRP1 CM, and cell lysates were analyzed by SDS-PAGE/immuno-
blotting for active β-catenin, total β-catenin, p-ERK1/2, and ERK1/2 (upper panel). The results were quantified using ImageQuant (lower panel).Available online http://breast-cancer-research.com/content/9/5/R63
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SkBr3/Wnt1 cells were treated with sFRP1 for 2 hours prior
to lysis of the cells, the level of ERK1/2 phosphorylation was
strongly decreased (Figure 4c). This strongly suggests that
the response in ERK1/2 phosphorylation toward Wnt1 treat-
ment or stable Wnt1 expression is Wnt ligand-specific. This
finding is supported by interference with WNT signaling down-
Figure 3
Short interfering RNA (siRNA)-mediated knockdown of Dishevelled (DVL) homologues results in decreased canonical wingless and integration site  growth factor (WNT) signaling, a reduction in basal epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase 1/2 (ERK1/2)  activation, and the induction of apoptosis in human breast cancer cells Short interfering RNA (siRNA)-mediated knockdown of Dishevelled (DVL) homologues results in decreased canonical wingless and integration site 
growth factor (WNT) signaling, a reduction in basal epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase 1/2 (ERK1/2) 
activation, and the induction of apoptosis in human breast cancer cells. (a) The indicated human breast cancer cell lines were transfected with pan-
DVL siRNA. Two thousand to 5,000 cells were seeded in triplicate in 12-well plates the day after the transfection, and the cell number was counted 
after 7 days using a Vi-Cell XR cell viability analyzer. DVL knockdown was verified by SDS-PAGE/immunoblotting (only DVL3 is shown). The levels 
of act. β-catenin, total β-catenin, the WNT target c-MYC, and poly(ADP-ribose)polymerase (PARP) were analyzed by SDS-PAGE/immunoblotting. 
The lower band (80 kDa) in the blot probed for PARP represents the cleavage product upon induction of apoptosis. α-Tubulin was used as a loading 
control. For quantification, act. β-catenin levels were normalized to total β-catenin and c-MYC was normalized to α-Tubulin expression. (b) The indi-
cated human breast cancer cell lines were transfected with pan-DVL siRNA and analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and EGFR 
Y845 phosphorylation. DVL2 levels are shown to monitor efficient knockdown of DVL, and α-Tubulin was used as loading control. For quantification, 
p-ERK1/2 was normalized to total ERK1/2 and p-EGFR Y845 was normalized to total EGFR expression.Breast Cancer Research    Vol 9 No 5    Schlange et al.
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Figure 4
Wnt1 induces rapid phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in human breast cancer cells Wnt1 induces rapid phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in human breast cancer cells. (a) Cultures of the indicated 
cell lines were treated for 20 minutes with Wnt1 conditioned medium (CM) or control CM, and lysates were analyzed by SDS-PAGE followed by 
immunoblotting for p-ERK1/2 and ERK1/2. (b) T47D cells were treated with control CM or Wnt1 CM, which was previously incubated for 2 hours 
with 30 μg/mL purified secreted Frizzled-related protein 1 (sFRP1) or phosphate-buffered saline as control. Cell lysates were analyzed by SDS-
PAGE/immunoblotting for p-ERK1/2 and p38 as loading control. (c) Stably Wnt1-transfected T47D and SkBr3 cells were treated for 2 hours with 
sFRP1 CM, control CM, or normal growth medium. Total lysates were analyzed by SDS-PAGE followed by immunoblotting for p-ERK1/2 and ERK1/
2. (d) T47D/Wnt1 and SkBr3/Wnt1 cells were seeded at 300,000 cells per well in a six-well plate the day before short interfering RNA (siRNA) 
transfection with either a LacZ control siRNA or pan-DVL siRNA. The cells were cultured for an additional 48 hours under normal growth conditions 
and 24 hours in 0.1% fetal calf serum before harvesting. Total lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2, ERK1/2, DVL1, 
DVL2, and DVL3, or α-Tubulin as a loading control. (e) T47D cultures were treated for the indicated times with 100% and 20% vol/vol Wnt1 CM. 
Total lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2 (upper panel). ERK activation was quantified after normaliza-
tion of signal intensity of p-ERK1/2 to total ERK1/2 using the ImageQuant software. ERK activity peaks at between 30 minutes and 1 hour (lower 
panel). (f) Wnt1-mediated effects are independent of β-catenin. T47D cells were infected with a retrovirus carrying an expression cassette for a 
short-hairpin RNA targeting β-catenin. Two independent shβ-catenin clones and a control pool infected with a short hairpin against bacterial LacZ 
were treated with control CM or Wnt1 CM for 20 minutes or 10 ng/mL EGF for 5 minutes. Total lysates were analyzed by SDS-PAGE/immunoblot-
ting for p-ERK1/2, ERK1/2, and β-catenin. DVL, Dishevelled.Available online http://breast-cancer-research.com/content/9/5/R63
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stream of the FZD receptor level through DVL knockdown that
abolishes the increase in ERK1/2 phosphorylation in T47D/
Wnt1 and SkBr3/Wnt1 cells (Figure 4d).
To assess the involvement of canonical β-catenin-dependent
WNT signaling in the activation of ERK1/2 pathway, we next
examined the kinetics of Wnt1-induced ERK1/2 activation
after treating T47D cells with concentrated and with five-fold
diluted Wnt1 CM. In both cases, ERK1/2 activation was rapid,
peaking at between 30 and 60 minutes and falling back to
basal by 8 hours (Figure 4e). Whereas the p-ERK1/2 levels
were lower in cells treated with diluted Wnt1 CM, the kinetics
were identical (Figure 4e). The rapid nature of ERK1/2 phos-
phorylation in response to Wnt1 makes it unlikely that tran-
scriptional activity driven by canonical WNT/β-catenin
signaling contributes to transactivation. However, to directly
exclude this, β-catenin was knocked down in T47D cells by
infection with an shRNA vector. Two independent knockdown
clones showing an approximately 70% decrease in β-catenin
levels and a control LacZ shRNA were analyzed (Figure 4f).
Treatment of both β-catenin knockdown clones and the con-
trol clone with Wnt1 CM led to a rapid increase in p-ERK1/2
levels to the same extent as seen in EGF-treated cells (Figure
4f). Taken together, these data demonstrate that, in human
breast cancer cells, Wnt1 activates the ERK1/2 pathway in a
WNT ligand- and DVL-dependent manner and this is inde-
pendent of canonical signaling via β-catenin stabilization.
Wnt1-induced ERK1/2 phosphorylation is EGFR-
dependent
We next explored whether activation of EGFR is induced by
Wnt1 and acts upstream of the observed ERK1/2 phosphor-
ylation. Overall EGFR phospho-tyrosine levels are 1.6 fold and
8.7 fold elevated in T47D/Wnt1 and SkBr3/Wnt1 cells over
the level in corresponding control transfected cells (Figure
5a). Treatment of T47D/Wnt1 cells with an EGFR-blocking
antibody (225) that prevents ligands from binding the receptor
causes a decrease in p-ERK1/2 to basal levels in the cells
(Figure 5b). Shedding of EGF-like ligands from their mem-
brane-bound form requires the activity of metalloproteases of
the MMP and/or ADAM families. MMP or ADAM activity is
required for the activation of the ERK1/2 pathway downstream
of Wnt1 as the inhibitor of metalloprotease activity
CGS27023A lowered Wnt1-induced ERK1/2 activity to basal
levels (Figure 5c). Finally, the Wnt1-mediated increase in
ERK1/2 activity was blocked by either pre-treatment of T47D
cells or treatment of T47D/Wnt1 and SkBr3/Wnt1 cells with
PKI166, an EGFR tyrosine kinase inhibitor (TKI) (Figure 5d)
[37]. Taken together, these data suggest that Wnt transacti-
vates EGFR via metalloprotease-dependent ligand
release)[19].
Wnt1-induced ERK phosphorylation requires Src kinase 
activity
As FZD receptors are structurally related to GPCRs and mem-
bers of the Src kinase family were reported to act in GPCR
ligand-induced EGFR transactivation)[19], we explored the
possibility that c-Src has a role in Wnt1-mediated EGFR trans-
activation. Initially, we tested whether Wnt1-expressing cells
Figure 5
Wnt1-induced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation depends on epidermal growth factor receptor (EGFR) activity Wnt1-induced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation depends on epidermal growth factor receptor (EGFR) activity. (a) 
EGFR was immunoprecipitated from 2 mg of whole cell lysate from T47D/Wnt1, T47D/vector, SkBr3/Wnt1, and SkBr3 vector cells and analyzed by 
SDS-PAGE/immunoblotting for p-Tyr and EGFR. The p-Tyr signal corresponding to EGFR was quantified using the ImageQuant software. (b) 
T47D/Wnt1 cells were pre-treated for 1 hour with monoclonal antibody 225 containing conditioned medium (CM), and lysates were analyzed by 
SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2. (c) T47D/Wnt1 cells were pre-treated for 1 hour with the metalloprotease inhibitor 
CGS27023A (50 μM) or dimethyl sulfoxide as control. Total lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2. (d) 
T47D cells were pre-treated for 1 hour with 2 μM PKI166 before treatment with Wnt1 CM or control CM. T47D/Wnt1 and SkBr3/Wnt1 cells were 
treated for 1 hour with 2 μM PKI166 prior to lysing the cells. Lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2. Tyr, 
tyrosine.Breast Cancer Research    Vol 9 No 5    Schlange et al.
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have elevated c-Src kinase activity by examining phosphoryla-
tion of the regulatory p-Tyr 416 in c-Src IPs. In SkBr3/Wnt1
cells, c-Src activity was increased two-fold over SkBr3/vector
cells (Figure 6a). T47D cells have high levels of active c-Src,
and no differences were observed between control and Wnt1-
expressing cells (data not shown).
Next, we examined the effects of CGP77675, an Src kinase-
selective TKI [38,39]. Treatment of T47D/Wnt1 and SKBR3/
Wnt1 cells with CGP77675 lowered ERK1/2 activity. Moreo-
ver, induction of p-ERK1/2 mediated by Wnt1 CM was
blocked by CGP77675 pre-treatment (Figure 6b). Since
CGP77675 blocks the activity of multiple Src family members
[38], we used MEFs from c-Src knockout mice that were trans-
fected with a c-Src-expressing vector or a control vector to
directly test the role of c-Src. Whereas EGF stimulated ERK1/
2 activity in both cell lines (although slightly less in c-Src
knockout fibroblasts) [39], Wnt1 treatment increased ERK1/2
activity in c-Src-transfected MEFs, but not in control MEFs
(Figure 6c). Interference with intracellular Ca2+ levels, PKC
signaling, or Gαi/o signaling, each of which is known to impact
on GPCR-induced EGFR transactivation, did not affect Wnt1-
induced ERK1/2 phosphorylation (data not shown). These
observations suggest that, as observed for many GPCR-acti-
vating ligands)[19], c-Src is also required for Wnt1-mediated
EGFR transactivation.
Wnt1 rescues breast cancer cells from growth arrest 
induced by anti-estrogen therapy
Ligand-mediated autocrine ERBB activation confers resist-
ance to anti-cancer agents [22], including the ER antagonist
4-HT [40]. Based on the ability of Wnt1 to activate EGFR and
ERK1/2 signaling in the ER+ T47D and MCF-7 breast tumor
cells (Figure 4a), we examined the effect of Wnt1 treatment on
their response to 4-HT.
Treatment of T47D and MCF-7 cells with 4-HT and PKI166
blocked proliferation by approximately 50% and 60%, respec-
tively; the combination of inhibitors is essentially additive in
both cell lines (Figure 7a,b). In T47D cells, Wnt1 treatment
almost completely rescued the anti-proliferative effect of 4-HT
(79% of control level, Figure 7a, upper panel). MCF-7 cells
were also significantly rescued from the anti-proliferative activ-
ity of 4-HT by Wnt1 (32% of control level, Figure 7b). PKI166-
treated T47D and MCF-7 cultures were both insensitive to
Wnt1 addition, showing the dominance of EGFR blockade.
Importantly, addition of PKI166 completely suppressed the
ability of Wnt1 to overcome the anti-proliferative activity of 4-
HT in both cell lines, showing the importance of autocrine
EGFR activation in the Wnt1-induced rescue. In line with this,
Western blot analysis reveals that the slight increase in p-
ERK1/2 levels upon Wnt1 treatment observed after 2 hours of
incubation (Figure 4e) is completely blocked using the more
potent dual EGFR/ERBB2 kinase inhibitor AEE788 [41] while
Figure 6
Src kinase is required for Wnt1-mediated extracellular signal-regulated kinase 1/2 (ERK1/2) activation Src kinase is required for Wnt1-mediated extracellular signal-regulated kinase 1/2 (ERK1/2) activation. (a) c-Src was immunoprecipitated from 
lysates of Wnt1-expressing or vector control-expressing SkBr3 cells. The immunoprecipates were analyzed by SDS-PAGE/immunoblotting for p-Src 
and Src, and the signals were quantified versus control levels using the ImageQuant program. (b) T47D cells were pre-treated with the Src kinase 
inhibitor CGP77675 (2 μM) or dimethyl sulfoxide (DMSO) for 1 hour before treatment for 20 minutes with Wnt1 conditioned medium (CM). T47D/
Wnt1 and SkBr3/Wnt1 cells were treated for 1 hour with CGP77675 or DMSO. Total lysates were analyzed by SDS-PAGE/immunoblotting for p-
ERK1/2 and ERK1/2. (c) Src-/- mouse embryonic fibroblasts transfected with a control plasmid or a wild type Src-expressing vector were treated 
with Wnt1 CM or control CM for 20 minutes. Total lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2. A representa-
tive result of three independent experiments is shown. EGF, epidermal growth factor; IP, immunoprecipitation; WB, Western blotting.Available online http://breast-cancer-research.com/content/9/5/R63
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4-HT treatment even enhances the activation of the ERK1/2
pathway slightly (Figure 7a, lower panel). After long-term treat-
ment (3 days) with 4-HT in the presence of Wnt1, p-ERK1/2
levels are still elevated over basal levels, but ERK1/2 phospho-
Figure 7
Wnt1 rescues breast tumor cells from the anti-proliferative effects of 4-hydroxytamoxifen (4-HT) Wnt1 rescues breast tumor cells from the anti-proliferative effects of 4-hydroxytamoxifen (4-HT). T47D (a) or MCF-7 (b) cells were treated with 4-HT 
(5 μM), PKI166 (5 μM), or a combination of both drugs for 7 or 6 days, respectively, in the presence or absence of Wnt1 conditioned medium (CM) 
or control CM. For control experiments, the solvents ethanol and dimethyl sulfoxide, respectively, were added in corresponding concentrations. Cul-
tures were re-fed with fresh medium and inhibitors after 3 days, before cell number (± standard error) was determined. For biochemical analysis, 
T47D cells were treated under corresponding conditions with 4-HT (5 μM), AEE788 (2 μM), or a combination of both in the absence or presence of 
Wnt1 CM or control CM for 2 hours or 3 days. Total lysates were analyzed by SDS-PAGE/immunoblotting for p-ERK1/2 and ERK1/2. *p < 0.05, **p 
< 0.005, unpaired Student t test. ERK1/2, extracellular signal-regulated kinase 1/2; n.s., difference not significant; WB, Western blotting.Breast Cancer Research    Vol 9 No 5    Schlange et al.
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rylation remains completely blocked by AEE788. These results
imply that Wnt1 overcomes the anti-proliferative effect of anti-
ER treatment in a manner that depends on EGFR activity.
Discussion
De-regulation of WNT signaling is a well-established hallmark
of certain types of human cancer, such as CRC and
melanoma, in which a high percentage of mutations in the β-
catenin destruction complex components APC and AXIN or in
β-catenin itself have been described [42]. Although mutations
of this type are rarely observed in breast cancer, we show here
that many breast cancer cell lines have autocrine activity of
WNT signaling and that blocking this pathway has multiple
biological effects. In breast cancer, activation of the Wnt path-
way is likely due to co-expression of WNT ligands and FZD
receptors (T Schlange, unpublished observations) [7,12-14].
WNT ligands play different roles in cancer biology depending
on the downstream pathways activated. Whereas canonical
Wnt signaling is required for G1 cell cycle progression in CRC
[43], the non-canonical ligand WNT5A negatively regulates
proliferation [44,45] but promotes migration in various cancer
types [46,47]. One potential mechanism contributing to path-
way activity might be loss of negative modulators of WNT sig-
naling [48], as decreased expression of sFRP1 is well
documented in human breast cancer [10,11,29]. Furthermore,
the loss of sFRP1 expression was recently shown to synergize
with c-MYC-induced tumorigenesis [49]. Extending the analy-
sis of Bafico and colleagues [21], we assayed the activation of
WNT signaling by DVL phosphorylation, the most proximal
read-out of FZD receptor activation, and found autocrine WNT
activity in a panel of human breast cancer cells with diverse
genetic alterations.
We show here that treatment of many breast tumor cell lines
with sFRP1 has a consistently negative effect on their prolifer-
ation by affecting the canonical WNT pathway. In addition,
ERK1/2 pathway activity is also decreased by sFRP1 treat-
ment in the majority of the cancer cells, with SkBr3 cells being
particularly sensitive. SkBr3 cells have high levels of ERBB
activity. The fact that sFRP1 decreases p-ERK1/2 levels sug-
gests that WNT-mediated ERBB transactivation has an impor-
tant role in maintaining ERK1/2 signaling in these tumor cells.
As SkBr3 cells have essentially no active β-catenin, sFRP1
effects on ERK1/2 activity might be the main cause for their
decreased proliferation in response to sFRP1 treatment. A
similar dependence on a non-canonical WNT signal was
observed in β-catenin-deficient mesothelioma cells [50], in
which siRNAs against WNT1 and DVL induced apoptosis in a
JNK (c-jun N-terminal kinase)-dependent manner. This finding
is particularly interesting given the inhibition of proliferation
and induction of apoptosis we observe in response to the
knockdown of all three DVL homologues in different breast
cancer cell lines. Interfering with WNT signaling at the DVL
level should block all autocrine activation [5]. sFRP1, on the
other hand, most likely binds only a subset of WNT ligands
[30,51], which might explain why sFRP1 treatment could not
completely block β-catenin stabilization or WNT-induced
ERK1/2 activity. In fact, compared with sFRP1 treatment, DVL
knockdown elicited a stronger negative effect on ERK1/2
activity in the breast cancer cell lines. BT474 and MCF-7 cells
are most resistant to both sFRP1 treatment and DVL knock-
down when compared with the other cell lines analyzed. In the
case of BT474, this is in line with relatively low levels of DVL
phosphorylation, indicating that this cell line is mostly inde-
pendent of autocrine WNT signaling. This shows that there is
differential sensitivity of human breast cancer cells with differ-
ent oncogenic pathways activated (for example, ERBB2 over-
expression, estrogen dependence) to inhibition of autocrine
WNT signaling.
Recently, blocking the FZD/DVL interaction using a small mol-
ecule targeting the PDZ domain of DVL was explored and
shown to inhibit the proliferation of cancer cell lines derived
from different types of cancer [52]. Our observations imply
that targeting this interaction or the use of a 'ligand trap' like
sFRP1 might be a valid approach to treat breast cancer by
interfering with the canonical WNT pathway as well as the
EGFR/ERK1/2 pathway. Inhibition of more than just one WNT
ligand or FZD receptor may overcome the problem of
functionally redundant expression of several family members
when specific antibodies are used [53-57]. In summary, our
observations on blocking autocrine WNT activity in human
breast cancer cells suggest an important role for WNT-
induced EGFR transactivation in the control of ERK1/2 signal-
ing and of proliferation.
It is also noteworthy that there is differential phosphorylation of
DVL isoforms in the panel of breast cancer cell lines. Perhaps
DVL family members are not redundant and might be activated
by different WNT/FZD complexes. Furthermore, DVL isoform
levels vary substantially in different breast cancer cell lines.
Therefore, it might be worth analyzing whether aspects of
tumor biology like proliferation and migration are differentially
regulated by these scaffolding proteins, potentially providing a
paradigm for the differentiation of non-canonical versus canon-
ical WNT signaling.
We show here that, in addition to activating the canonical
Wnt/β-catenin pathway, Wnt1 transactivates EGFR and stim-
ulates ERK1/2 activity in many human breast cancer cells. This
Wnt1-mediated response is similar to EGFR transactivation
induced by many GPCRs)[19]. In fact, various lines of
evidence, including the GPCR-like heptahelical structure of
the FZD receptor family and genetic data from Drosophila,
suggest that these receptors have biological similarities [58-
60]. Although we could not block Wnt1-induced ERK1/2
activation using pertussis toxin (PTX) to block Gαi/o proteins,
this still leaves the possibility that PTX-insensitive Gα proteins
mediate the effects of WNT/FZD signaling. Indeed, it wasAvailable online http://breast-cancer-research.com/content/9/5/R63
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shown that Gαq/11 group proteins contribute to the activation
of canonical WNT signaling [60,61].
Our results also show that c-Src has an important role in
Wnt1-driven EGFR transactivation. Wnt1 was able to
transactive EGFR in Src-expressing MEFs, but not in Src
knockout MEFs. Furthermore, an Src kinase inhibitor abol-
ished the effects of Wnt1 on ERK1/2 activation in human
breast cancer cell lines and Src kinase activation was
increased in SkBr3/Wnt1 cells. Src kinase has also been
implicated in GPCR-mediated EGFR transactivation)[19]. Src
kinase might act directly downstream of GPCRs and FZD
receptors via its interaction with ADAMs and MMPs [62-65].
Association of Src kinases with these enzymes might regulate
their proteolytic activity and subcellular localization [66], lead-
ing to an increase in ERBB ligand shedding and autocrine
receptor activation. Since we observed that neither metallo-
protease inhibitors nor an EGFR-blocking antibody completely
blocked Wnt1-induced ERK1/2 activation, this might reflect a
direct effect of Src kinase on EGFR activity due to its ability to
phosphorylate the receptor at Tyr 845 [67]. The involvement
of WNT-induced Src activity on EGFR activation is corrobo-
rated by our observation that the knockdown of DVL
decreased the level of Tyr 845 phosphorylation in several
breast cancer cell lines.
WNT signaling has previously been linked to the activation of
Src and ERK1/2 in NIH3T3 cells and in osteoblast progenitors
[68-70], and recently EGFR was shown to be involved in
ERK1/2 activation downstream of purified Wnt3a [71]. How-
ever, these studies rely on overexpression or treatment with
recombinant proteins and did not link the transactivation to
autocrine signaling processes. It was recently shown that
Wnt1 is induced by progesterone receptor (PgR) signaling in
T47D breast cancer cells and that it is required for EGFR
transactivation by a PgR agonist in an Src- and metallopro-
tease-dependent manner [72]. These results are interesting to
consider in light of the data presented in this paper. It is pos-
sible that the rapid effects of steroid hormones leading to sus-
tained proliferation or survival of breast tumor cells proceed by
establishing an autocrine loop of EGFR activity that is linked,
in part, to Wnt1 production. It will be important to see whether
results from the T47D breast cancer model are clinically rele-
vant in primary breast tumors, many of which overexpress
Wnt1 [13].
EGFR activity is known to play a role in endocrine therapy
resistance (for example, in MCF-7 cells) [73]. In fact, there are
increased β-catenin levels and increased expression of WNT
pathway target genes in these resistant cells [74], further
implicating WNT pathway activity in endocrine resistance. Our
data also show the potential importance of autocrine WNT sig-
naling in response to anti-hormonal therapies. Wnt1 treatment
of the ER+ MCF-7 and T47D cells rescued them from the anti-
proliferative action of 4-HT, and this was blocked by treatment
with an EGFR TKI, showing the importance of autocrine EGFR
signaling in the Wnt1 rescue.
Conclusion
Our results support the concept that therapeutic interference
with autocrine WNT signaling might be a useful strategy for
targeting breast cancer. Furthermore, blocking the pathway at
the level of WNT/FZD/DVL, in contrast to targeting the β-cat-
enin/TCF complex [75], would not only impact on canonical
signaling but also provide a novel interface for interfering with
autocrine EGFR activity, an important target in breast cancer
[22,32]. In Figure 8, we propose a model that incorporates the
data presented in this paper.
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